Literature DB >> 20435660

Long-term survival and risk factors for recurrence in stage I non-small cell lung cancer patients with tumors up to 3 cm in maximum dimension.

Ryo Maeda1, Junji Yoshida, Genichiro Ishii, Tomoyuki Hishida, Keiju Aokage, Mitsuyo Nishimura, Yutaka Nishiwaki, Kanji Nagai.   

Abstract

BACKGROUND: The purpose of this study was to evaluate patients with stage I non-small cell lung cancer (NSCLC) and tumors up to 3 cm in maximum dimension who underwent surgical resection on the revised TNM classification and to investigate the risk factors for recurrence.
METHODS: Between 1994 and 2003, 713 consecutive stage I NSCLC patients with tumors up to 3 cm in maximum dimension underwent complete resection. Recurrence-free probability was estimated from the date of the primary tumor resection to the date of the first recurrence or the last follow-up using the Kaplan-Meier method.
RESULTS: The recurrence-free probability of stage I NSCLC patients with tumors up to 3 cm in maximum dimension was 87% at 5 years. On multivariate analyses, three variables were shown to be independently significant recurrence risk factors: histologic differentiation (hazard ratio, 2.3), intratumoral vessel invasion (hazard ratio, 2.9), and visceral pleural invasion (VPI) (hazard ratio, 1.8). According to subgroup analyses combining these three risk factors, the 5-year recurrence-free probability was 94% for patients with zero or one factor (n = 492) and 71% for patients with two or three factors (n = 221), respectively (P < .001).
CONCLUSION: In stage I NSCLC patients with tumors up to 3 cm in maximum dimension, we identified three risk factors for recurrence that independently increase their risk of recurrence. In addition to VPI, histologic differentiation and intratumoral vessel invasion should be examined and their data collected for the next revision of the TNM staging system.

Entities:  

Mesh:

Year:  2010        PMID: 20435660     DOI: 10.1378/chest.09-3046

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  11 in total

1.  Visceral pleural invasion does not affect recurrence or overall survival among patients with lung adenocarcinoma ≤ 2 cm: a proposal to reclassify T1 lung adenocarcinoma.

Authors:  Jun-Ichi Nitadori; Christos Colovos; Kyuichi Kadota; Camelia S Sima; Inderpal S Sarkaria; Nabil P Rizk; Valerie W Rusch; William D Travis; Prasad S Adusumilli
Journal:  Chest       Date:  2013-11       Impact factor: 9.410

2.  Preoperative bronchoscopic cancer confirmation does not increase risk of recurrence in stage1A non-small cell lung cancer.

Authors:  Jiro Abe; Toshimasa Okazaki; Naohiko Kikuchi; Satomi Takahashi; Akira Sakurada; Yoshinori Okada
Journal:  Gen Thorac Cardiovasc Surg       Date:  2018-03-21

3.  FDG uptake at the bronchial stump after curative lobectomy for non-small cell lung cancer.

Authors:  Caroline Keyzer; Florence Corbusier; Eirini Kyratzi; Youri Sokolow; Pierre Alain Gevenois; Serge Goldman
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-10-28       Impact factor: 9.236

Review 4.  Integrated imaging of non-small cell lung cancer recurrence: CT and PET-CT findings, possible pitfalls and risk of recurrence criteria.

Authors:  Andrea Caulo; Saeed Mirsadraee; Fabio Maggi; Lucia Leccisotti; Edwin J R van Beek; Lorenzo Bonomo
Journal:  Eur Radiol       Date:  2011-10-04       Impact factor: 5.315

5.  A retrospective comparative analysis of elderly and younger patients undergoing pulmonary resection for stage I non-small cell lung cancer.

Authors:  Byungjoon Park; Genehee Lee; Hong Kwan Kim; Yong Soo Choi; Jae Il Zo; Young Mog Shim; Jhingook Kim
Journal:  World J Surg Oncol       Date:  2016-01-19       Impact factor: 2.754

6.  Prognostic impact of count of extratumoral lymphatic permeation in lung adenocarcinoma and its relation to the immune microenvironment.

Authors:  Takahiro Niimi; Tokiko Nakai; Keiju Aokage; Kenta Tane; Tomohiro Miyoshi; Joji Samejima; Saori Miyazaki; Tetsuro Taki; Naoya Sakamoto; Shingo Sakashita; Reiko Watanabe; Motohiro Kojima; Kenji Suzuki; Masahiro Tsuboi; Genichiro Ishii
Journal:  Cancer Sci       Date:  2022-02-19       Impact factor: 6.716

7.  Treatment Modality for Stage IB Peripheral Non-Small Cell Lung Cancer With Visceral Pleural Invasion and ≤3 cm in Size.

Authors:  Weijia Huang; Han-Yu Deng; Ming-Ying Lin; Kai Xu; Yu-Xiao Zhang; Chi Yuan; Qinghua Zhou
Journal:  Front Oncol       Date:  2022-02-18       Impact factor: 6.244

8.  Lymph but Not Blood Vessel Invasion Is Independent Prognostic in Lung Cancer Patients Treated by VATS-Lobectomy and Might Represent a Future Upstaging Factor for Early Stages.

Authors:  Melanie Biesinger; Nele Eicken; Alexander Varga; Michael Weber; Milos Brndiar; Georg Erd; Peter Errhalt; Klaus Hackner; Sarah Hintermair; Alexander Petter-Puchner; Axel Scheed; Elisabeth Stubenberger; Bahil Ghanim
Journal:  Cancers (Basel)       Date:  2022-04-08       Impact factor: 6.575

9.  Impact of extratumoral lymphatic permeation on postoperative survival of non-small-cell lung cancer patients.

Authors:  Yuki Matsumura; Tomoyuki Hishida; Yoshihisa Shimada; Genichiro Ishii; Keiju Aokage; Junji Yoshida; Kanji Nagai
Journal:  J Thorac Oncol       Date:  2014-03       Impact factor: 15.609

10.  [Exploration of Postoperative Follow-up Strategies for Early Staged NSCLC Patients on the Basis of Follow-up Result of 416 Stage I NSCLC Patients after Lobectomy].

Authors:  Liang Dai; Wanpu Yan; Xiaozheng Kang; Hao Fu; Yongbo Yang; Haitao Zhou; Zhen Liang; Hongchao Xiong; Yao Lin; Keneng Chen
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2018-03-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.